Pershing Square Sohn Cancer Research Alliance Invites Applications
PSSCRA Opens Applications for 2025 Cancer Research Prize
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) is excited to announce that it has opened applications for the coveted 2025 Pershing Square Sohn Cancer Prize. This annual award aims to support rising stars in cancer research by providing significant funding to innovative scientists dedicated to making a breakthrough in the field. The prize involves a generous grant of $250,000 per year for a period of three years, aimed at empowering six researchers each year who are based in the greater New York City area.
Empowering Scientific Innovation
The Pershing Square Sohn Cancer Prize is particularly important as it encourages early-career scientists to pursue visionary and potentially high-risk cancer research projects. Often, at a stage when traditional funding avenues may be lacking, the Prize provides a vital lifeline for researchers striving to make impactful contributions. As Bill Ackman, a trustee of the Pershing Square Foundation remarked, countless past winners have made significant strides in cancer research, paving the way for a more collaborative and innovative environment.
Eligibility and Application Process
To be eligible for the award, applicants should have between two to six years of experience leading their own laboratories as of the award start date in July 2025. Additionally, qualifying candidates must possess an advanced degree such as a PhD, MD, or MD-PhD and should be affiliated with a research institution in the greater New York City area. The deadline for submitting a Letter of Intent is fast approaching, with a cutoff date set for late October 2024. Detailed information regarding the application process and eligibility criteria can be found on the official application submission portal.
Supporting Scientists at Critical Stages
Over its years of operation, the PSSCRA has provided funding and support to 71 talented investigators hailing from 13 esteemed academic research institutions. This highly competitive Prize not only underwrites important research but also connects winners with leaders in the pharmaceutical and biotech sectors. This creates a unique platform for showcasing their work to various audiences, including scientific, business, and philanthropic communities.
Testimonials from Past Winners
Numerous past winners have voiced their gratitude for the financial support received through the Pershing Square Sohn Cancer Prize. For instance, David Simon, a 2024 Prize winner from Weill Cornell Medicine, highlighted the transformative impact of the funding on his project, which otherwise would have been shelved due to a lack of financial resources. Similarly, Christine Chio, a 2021 Prize recipient, credited the award with providing her invaluable networking opportunities and a broader scientific perspective.
A Legacy of Commitment and Vision
As the Prize enters its twelfth year, President of The Pershing Square Foundation and Co-Founder of the PSSCRA, Olivia Tournay Flatto, expressed her ongoing commitment to nurturing a community of diverse scientists. This initiative is more than just about funding; it acknowledges the quality of applications and the unwavering dedication of reviewers who play a crucial role in the selection process.
About the Pershing Square Sohn Cancer Research Alliance
Established in 2013, the PSSCRA has committed over $43 million to support groundbreaking research in the field of cancer. By fostering collaboration between academia and industry, the Alliance is dedicated to catalyzing innovations that could lead to life-saving cures for cancer. Annually, the Pershing Square Sohn Cancer Prize is awarded to early-career scientists engaged in pioneering cancer research, serving as an essential acknowledgment of their efforts and potential.
Frequently Asked Questions
What is the Pershing Square Sohn Cancer Prize?
The Pershing Square Sohn Cancer Prize is an annual award that provides $250,000 each year for three years to rising stars in cancer research in the New York City area.
Who is eligible to apply for the Prize?
Applicants should have 2-6 years of experience running their own labs, hold a high-level degree such as a PhD or MD, and be affiliated with a New York area research institution.
How many winners are selected each year?
Each year, the Prize awards six recipients who have demonstrated innovative and impactful research proposals.
What are the benefits of winning the Prize?
Winners receive significant funding for their research and gain access to exclusive networking opportunities with industry leaders.
When is the application deadline?
The deadline for submitting a Letter of Intent is set for late October 2024. Prospective applicants should check the PSSCRA website for specific dates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- AIRAmed and Memory Treatment Centers Collaborate on Alzheimer’s Research
- Collaboration to Enhance Colorectal Cancer Treatment Options
- Anbogen and BeiGene Join Forces to Explore Cancer Treatments
- XCMG and Shell Forge Alliance Enhances Machinery Performance
- Photocure Launches Program to Enhance Bladder Cancer Care
- Lam Research's Stock Surges Amid Semiconductors' Rise
- Molecular Partners Set to Present Groundbreaking Cancer Therapy
- Collaboration Between Defense Metals and Saskatchewan Research
- BeiGene Updates on FDA Advisory Vote for TEVIMBRA in Cancer Care
- Transforming Brand Connections: MSquared's Metaverse Revolution
Recent Articles
- TD Cowen Retains Hold Rating on McDonald's Amid Innovations
- T-Mobile Plans to Offer Senior Notes for Corporate Growth
- Masco Corporation Reveals Date for Q3 Earnings Call
- Solanex AI DEX Set to Transform Trading Experience on Solana
- Altamaha Green Energy's Renewable Project Receives Approval
- Discover Hamster Cash: The Next Evolution in Gaming Rewards
- ATX Networks Enhances Broadband Solutions with Charter
- Dexcom and Partners Launch National Glucose Week for Awareness
- Chenega Corporation and CyberSheath Achieve JSVA Validation Triumph
- Transforming Student Travel: Flyla and SheerID Unite for Affordable Fares
- Flora Food Group Expands Operations with New Manufacturing Hub
- Enhanced Lymphoma Panel from Integrated DNA Technologies
- Q2's New CFO, Jonathan Price, Steps into Key Role
- Successful Reorganization of First Trust Funds with abrdn
- Peachtree Group Expands Portfolio with New Hotel Investment
- AMD's Lisa Su Discusses the Future of Custom AI Chips
- Forrester Celebrates 2024 Award Winners at Innovation Summit
- Aether Fuels Collaborates with JetBlue on Sustainable Aviation Fuel
- Blooming Health Commits to Enhance Health Equity Nationwide
- Helix Labs Secures $2 Million to Enhance Cardano's DeFi Landscape
- Fifth Third’s Newline™ Recognized as Top Embedded Finance Solution
- Future Tech Boosts Leadership with Mike Watkinson's Appointment
- PeopleOne Health and RosenCare Celebrate New Orlando Facility
- Chelsea Lighting Earns Top Recognition in New York Business List
- Sprout Social Partners with Carahsoft for Enhanced Public Services
- Ryan Greenier Takes Helm as CFO at Horace Mann Corporation
- EquityZen Strengthens Leadership Team with Key Appointments
- Bollinger Motors Marks a Historic Achievement with B4 Truck Launch
- Leadership Updates at MAI Capital Management Strengthen Growth
- Capital Power's Vision for a Sustainable Energy Future
- Growth Trends and Innovations in the Industrial Vacuum Market
- Exploring Financial Security Challenges in Modern America
- KRAIBURG TPE Americas Unveils Next-Gen Lightweight TPE Solutions
- Dairy Packaging Market Growth: Key Trends and Developments
- Butterfly Completes $300 Million Loan for Milk Specialties Growth
- Exploring the Antibiotics Market Growth Vision for 2031
- Surging Demand in Fraud Detection and Prevention Marketplace
- Revolving Store Launches New Location, Elevating NYC Retail Experience
- Top Institutions Promoting Social Mobility: A 2024 Overview
- Delta Corp and Kaival Brands Join Forces for Major Merger
- TextUs Welcomes Andrew Davis as VP of Marketing for Growth
- Barings Strengthens Position with Financing for BKF Engineers
- Banzai to Share Key Updates in Upcoming Shareholder Call
- Ann Gallo Joins Piper Sandler Companies' Leadership Team
- Quad Partners with Google Cloud for Innovative AI Solutions
- Two Roads Consulting Celebrates Major Wins for Workplace Excellence
- Christina Cates Launches Culinary Confidential Talk Show on AM 970
- Ocean Park Asset Management Enhances Advisor Portfolio Access
- Delta Corp Holdings Merges with Kaival Brands Innovations
- Achievers Unveils Innovative AI Tool to Enhance Workplace Inclusion